Axxam is a member of the REsolution consortium

Axxam announces its participation in the REsolution consortium, a public-private research partnership supported by the Innovative Medicines Initiative (IMI), to accelerate research in the field of solute carrier (SLC) class of transporters.

read more

Axxam acquires Hit Discovery Constance

Axxam is proud to announce the entire acquisition of the share capital of Hit Discovery Constance GmbH (“HDC”). As a consequence, HDC founded in 2014 as a joint venture between Axxam, Centre for Drug Design and Discovery of KU Leuven and Lead Discovery Center GmbH, is now a subsidiary of Axxam.

read more

Symegold library for drug discovery services

Thanks to the long-standing collaboration with Symeres (recently rebranded from MercachemSyncom), Axxam has access to an additional library of approx. 80,000 lead-like compounds synthetized at Symeres, named Symegold library, for use in high-throughput screens.

read more

Selonterra and Axxam Enter into Drug Discovery Collaboration

Selonterra and Axxam Enter into Drug Discovery Collaboration June 16, 2020 San Mateo, California (USA) and Milan, Italy - Selonterra, Inc., a biotechnology company developing transformative therapies for neurodegenerative disorders, and Axxam S.p.A., a leading...

read more